Capital Fund Management S.A. Makes New Investment in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Capital Fund Management S.A. acquired a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 13,348 shares of the company's stock, valued at approximately $1,075,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its stake in shares of PROCEPT BioRobotics by 11.9% in the fourth quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after purchasing an additional 866,328 shares in the last quarter. Vanguard Group Inc. raised its position in shares of PROCEPT BioRobotics by 6.1% in the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after acquiring an additional 297,075 shares in the last quarter. Alliancebernstein L.P. raised its stake in PROCEPT BioRobotics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock valued at $141,110,000 after buying an additional 218,148 shares during the last quarter. Wellington Management Group LLP boosted its stake in PROCEPT BioRobotics by 38.8% in the 4th quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after purchasing an additional 416,819 shares in the last quarter. Finally, State Street Corp increased its position in shares of PROCEPT BioRobotics by 5.9% during the third quarter. State Street Corp now owns 1,179,514 shares of the company's stock valued at $94,503,000 after acquiring an additional 66,175 shares in the last quarter. Institutional investors own 89.46% of the company's stock.

Insider Buying and Selling

In related news, CEO Reza Zadno sold 5,475 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. This represents a 3.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. Insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Stock Up 0.4 %

PRCT stock traded up $0.22 during midday trading on Friday, hitting $53.03. The company's stock had a trading volume of 868,416 shares, compared to its average volume of 781,268. The firm has a 50-day simple moving average of $59.41 and a 200-day simple moving average of $74.83. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $2.91 billion, a P/E ratio of -27.19 and a beta of 1.09. PROCEPT BioRobotics Co. has a 52-week low of $47.04 and a 52-week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. As a group, equities analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

PRCT has been the subject of several research reports. Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Truist Financial cut their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus price target of $91.43.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).